Medisun Precision Medicine

Medisun Precision Medicine Ltd. is a development stage company based in Majuro, the Republic of the Marshall Islands, focused on creating targeted therapies for neurological conditions, primarily in the United States. The company's key initiatives include the ACX-31 program, which aims to deliver the chemotherapy drug temozolomide in conjunction with BCNU directly to brain tumors. Additionally, Medisun is developing BranchPoint, a microinjection brain catheter designed for the precise delivery of therapeutics to complex brain areas. The company has entered into a collaboration agreement with DelMar Pharmaceuticals to advance the ACX-31 program and has a consulting agreement with Lim Development Group for the development and commercialization of the BranchPoint device. Formerly known as Accurexa, Inc., Medisun Precision Medicine Ltd. was established in 2012 and rebranded in June 2017.